Navigation Links
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
Date:11/12/2013

rological Association, recently presented complete Phase I NSI-566/ALS trial data at the annual ANA meeting, which  showed a clear slowing of disease progression or actual improvement for more than 700-to-approximately-850 days post-surgery, in six non-bulbar ALS  patients who were treated early in the course of their disease. All patients in Phase II are also ambulatory and within approximately two years of the onset of symptoms of the disease," said Dr. Johe. "The results from the complete Phase I data will be made public after they are published in a peer-reviewed scientific journal anticipated later this year.

"Looking ahead, our NSI-566/stroke Phase I/II trial at BaYi Brain Hospital, in Beijing, is expected to be underway later in the fourth quarter. This trial will treat with one-time intracerebral injections of cells directly into the ischemic stroke area," continued Dr. Johe. "The first phase will determine the maximum safe dose in up to 18 patients, and is expected to be completed in seven or eight months. Phase II will advance to a multicenter, randomized, controlled single-blind study with up to 100 patients, and is designed to evaluate efficacy and safety for clinical proof-of-concept. Also, of note, we continue to make progress towards commencement of the FDA-approved NSI-566/chronic spinal cord injury Phase I trial in the first quarter of 2014. This trial, which will treat eight patients with T2-T12 complete paralysis, uses the same cells and methodology as our ALS trial.  

"The recent publication of an animal study by our collaborators at the University of California, Irvine, provided proof of principle for NSI-566 in the amelioration of cognitive dysfunction induced by brain irradiation, a common treatment for brain cancer in humans. In the study, rats injected with the cells two days after brain irradiation demonstrated a reduction in radiation-induced cognitive dysfunction. This is an important validation for the ongoi
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... and Brent Butler 2 , ... Massachusetts, USA , ... , Introduction , ... carried out using manual pipetting. As the demand for greater throughput of plate ...
... , , , , FLEXSTATION IS A ... SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS , , ... , EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR ... G q -coupled receptors are transmembrane proteins that are responsible ...
... , HOMOGENEOUS ASSAY , , ... PROCEDURE , , COMPATIBLE WITH MORE TARGETS ... , The ... detecting changes,in intracellular calcium concentration.,Specifically, this fast and simple fluorescencebased,assay allows the ...
Cached Biology Technology:96 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 296 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 4Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 2Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 3Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 4Calcium Plus Assay Kit, Superior Detection for Specialized Targets 2Calcium Plus Assay Kit, Superior Detection for Specialized Targets 3
(Date:4/23/2014)... of Public Health-Bloomington has bolstered the link between red ... association between heme iron, found only in meat, and ... that heme iron consumption increased the risk for coronary ... found between nonheme iron, which is in plant and ... study was published online ahead of print in the ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... the likelihood of an accurate group decision increases with ... when a collective faces a variety of factors ... University researchers report that smaller groups actually tend to ... excessively focused on only certain pieces of information. , ... known about collective intelligence, or the "wisdom of crowds," ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... Va. The availability of new genome sequencing ... to test an intriguing hypothesis about how agricultures ... plant pathogens. Boris Vinatzer, assistant professor of ... College of Agriculture and Life Sciences, has received ...
... GAINESVILLE, Fla. Using the genetic equivalent of an ... the Earth endured a massive cooling period between 500 ... (Feb. 7) in the journal Nature, researchers from the ... and the biotechnology company DNA2.0 describe how they reconstructed ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Scientists rebuild ancient proteins to reveal primordial Earth's temperature 2Madagascar's tortoises are crawling toward extinction, groups say 2
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Biology Products: